USPTO serial 87052324
Serial No. 87052324
Reviewed by CopyMark Law Group
Reg. 5332632Status 710
- Filing date
- Status date
- Registration date
- Nov 14, 2017
- Examiner
- BLAZICH, JOAN MICHELE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with Serial No. 87052324?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Mark Harrison
MARK HARRISON VENABLE LLPP.O. BOX 34385WASHINGTON, DC 20043UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals for use in industry and science; chemicals test kits for in vitro testing for laboratory research purposes; biochemicals, namely, monoclonal antibodies and antibody fragments all being proteins for in vitro scientific and laboratory research use; biochemicals, namely, monoclonal antibodies and antibody fragments all being proteins for scientific and laboratory research use; biochemical, namely, monoclonal antibodies and antibody fragments all being protein in raw material form for scientific research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for scientific and laboratory in vitro diagnostic use; antibodies and antibody fragments all being proteins for industrial use in the discovery, preclinical and clinical development of therapeutic products | SECTION 8 - CANCELLED | — |
| 005 | Pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders and dermatological diseases; veterinary preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders and dermatological diseases; therapeutic pharmaceutical preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes; antibodies being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders and dermatological diseases; antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ and tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders and dermatological diseases; monoclonal antibody therapeutic preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ and tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders and dermatological diseases; antibodies and antibody fragments being diagnostic reagents for medical and veterinary diagnostics; antibodies and antibody fragments for use in the discovery, preclinical and clinical development of therapeutic products; antibodies and antibody fragments being therapeutic pharmaceuticals for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ and tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders and dermatological diseases for use in the manufacture of therapeutic products | SECTION 8 - CANCELLED | — |
| 031 | Live animals; live mice | SECTION 8 - CANCELLED | — |
| 040 | Treatment and transformation of materials for others, namely, the manufacture of chemicals, biologicals, antibodies and antibody fragments; contract manufacturing services in the field of chemicals, biologicals, antibodies and antibody fragments; custom manufacture of therapies using antibodies and antibody fragments | SECTION 8 - CANCELLED | — |
| 042 | Scientific and technological services, namely, scientific research, analysis and testing, and research and design in the field of therapeutic pharmaceuticals; scientific laboratory services; laboratory services in the field of antibodies and antibody fragments; research in the field of the development of antibodies and antibody fragments; provision of scientific information in the field of antibodies and antibody fragments for medical and veterinary purposes; engineering of antibodies and antibody fragments; scientific services, namely, the discovery, preclinical and clinical development of therapeutic products; consultancy services relating thereto, namely, therapeutic products | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Crescendo Biologics Limited
- Other trademarks owned by Crescendo Biologics Limited
- Other trademarks owned by Crescendo Biologics Limited
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 031
- Other trademarks in Class 040
- Other trademarks in Class 042
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 28, 2024 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Nov 14, 2022 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Nov 14, 2017 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 29, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 29, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 9, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 26, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 19, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 19, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 18, 2017 | ALIE | ASSIGNED TO LIE | — |
| Jun 9, 2017 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Apr 28, 2017 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Apr 28, 2017 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Apr 28, 2017 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Oct 28, 2016 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Oct 28, 2016 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Oct 28, 2016 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Oct 28, 2016 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 28, 2016 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Oct 28, 2016 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Oct 28, 2016 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 20, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 20, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 20, 2016 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 15, 2016 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 15, 2016 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 15, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 12, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 7, 2016 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Jun 4, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 31, 2016 | NWAP | NEW APPLICATION ENTERED | — |